- Home
- NL vs LRMR Comparison
NL vs LRMR Comparison
Compare NL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NL
- LRMR
- Stock Information
- Founded
- NL 1891
- LRMR N/A
- Country
- NL United States
- LRMR United States
- Employees
- NL N/A
- LRMR N/A
- Industry
- NL Major Chemicals
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- NL Industrials
- LRMR Health Care
- Exchange
- NL Nasdaq
- LRMR Nasdaq
- Market Cap
- NL 389.8M
- LRMR 426.9M
- IPO Year
- NL N/A
- LRMR N/A
- Fundamental
- Price
- NL $7.66
- LRMR $3.96
- Analyst Decision
- NL Sell
- LRMR Strong Buy
- Analyst Count
- NL 1
- LRMR 8
- Target Price
- NL $6.00
- LRMR $19.63
- AVG Volume (30 Days)
- NL 37.6K
- LRMR 1.1M
- Earning Date
- NL 11-06-2024
- LRMR 10-30-2024
- Dividend Yield
- NL 4.03%
- LRMR N/A
- EPS Growth
- NL N/A
- LRMR N/A
- EPS
- NL 1.19
- LRMR N/A
- Revenue
- NL $150,690,000.00
- LRMR N/A
- Revenue This Year
- NL $2.18
- LRMR N/A
- Revenue Next Year
- NL $2.50
- LRMR N/A
- P/E Ratio
- NL $6.51
- LRMR N/A
- Revenue Growth
- NL N/A
- LRMR N/A
- 52 Week Low
- NL $5.00
- LRMR $3.01
- 52 Week High
- NL $9.42
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- NL 43.15
- LRMR 31.99
- Support Level
- NL $7.52
- LRMR $3.74
- Resistance Level
- NL $8.16
- LRMR $4.27
- Average True Range (ATR)
- NL 0.46
- LRMR 0.45
- MACD
- NL -0.05
- LRMR 0.03
- Stochastic Oscillator
- NL 10.00
- LRMR 43.98
About NL NL Industries Inc.
NL Industries Inc operates in the component products industry through its majority-owned subsidiary, CompX International Inc. It manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. CompX has three production facilities in the United States, through which it produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.